Allworth Financial LP Sells 49,306 Shares of Johnson & Johnson $JNJ

Key Points

• Allworth Financial reduced its Johnson & Johnson stake by 12%, selling 49,306 shares and retaining 362,958 shares valued at approximately $92.2 million. Hedge funds and institutional investors collectively own 69.55% of J&J.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $274.13. Recent targets range from $282 to $320, although one analyst downgraded the stock to “Hold.”
• J&J reported quarterly earnings and revenue above expectations, with year-over-year revenue growth of 6.6%, and maintains a quarterly dividend of $1.34 per share, or a 2.0% annualized yield. Investors are also watching potential value from a DePuy Synthes divestiture and risks from a failed mid-stage depression-drug trial.

Allworth Financial LP trimmed its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 12.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 362,958 shares of the company's stock after selling 49,306 shares during the quarter. Allworth Financial LP's holdings in Johnson & Johnson were worth $92,181,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Auto Owners Insurance Co boosted its holdings in Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock valued at $1,436,633,000 after acquiring an additional 69,108,368 shares during the period. Norges Bank bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $6,924,523,000. Capital World Investors purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $2,005,942,000. Jupiter Topco LLC bought a new position in shares of Johnson & Johnson in the second quarter worth about $1,967,399,000. Finally, Diamant Asset Management Inc. grew its holdings in shares of Johnson & Johnson by 24,436.5% in the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company's stock worth $109,338,000 after purchasing an additional 4,454,778 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on JNJ. Argus set a $300.00 price target on Johnson & Johnson in a report on Wednesday, July 29th. Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $272.00 to $282.00 and gave the stock an "overweight" rating in a report on Monday, August 3rd. Wall Street Zen downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. TD Cowen increased their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a research note on Monday, July 13th. Finally, UBS Group started coverage on shares of Johnson & Johnson in a report on Wednesday, September 2nd. They set a "buy" rating and a $320.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $274.13.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the firm's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. This trade represents a 50.06% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 87,569 shares of company stock valued at $23,064,544 in the last quarter. Insiders own 0.16% of the company's stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Potential $20 billion DePuy Synthes sale could unlock value. Apollo Global Management is reportedly in talks to acquire J&J’s DePuy Synthes orthopedics business, which generated approximately $9.3 billion in 2025 revenue. A sale or spinoff could sharpen J&J’s focus and return capital to shareholders. Apollo and J&J Face a High-Stakes Orthopedics Deal
• Positive Sentiment: Rybrevant delivers strong lung-cancer results. J&J reported that Rybrevant plus chemotherapy produced a 34.3-month median overall survival in EGFR exon 20 insertion-positive non-small-cell lung cancer, described as the longest reported result for this population. Separate data also showed fewer treatment-related events with the Rybrevant Faspro and Lazcluze combination, supporting the oncology pipeline and potential commercial momentum. Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival
• Positive Sentiment: Analyst and defensive-investment support remain favorable. TD Cowen maintained a Buy rating with a $300 price target, citing oncology momentum and the possible DePuy Synthes transaction. J&J is also being highlighted as a reliable dividend and defensive healthcare holding, which may attract investors during market volatility. J&J: Oncology Momentum and Potential $20B DePuy Synthes Divestiture Support Buy Rating
• Neutral Sentiment: Investors are monitoring strategic and fundamental developments. Attention is focused on J&J’s ability to achieve double-digit growth while Stelara faces biosimilar competition. Recent institutional activity has been mixed, while reported insider transactions consisted entirely of sales over the past six months.
• Negative Sentiment: Clinical setback hits a partnered depression treatment. JNJ-5120, also known as PIPE-307, failed to meet the primary endpoint in the Phase 2 MOONLIGHT-1 trial for major depressive disorder. J&J is reviewing additional data, but the failure reduces confidence in this portion of its drug-development pipeline. Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $266.94 on Wednesday. Johnson & Johnson has a fifty-two week low of $173.33 and a fifty-two week high of $281.07. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market capitalization of $643.29 billion, a price-to-earnings ratio of 30.93, a PEG ratio of 2.54 and a beta of 0.24. The stock's 50-day simple moving average is $263.17 and its 200-day simple moving average is $246.23.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. Johnson & Johnson's revenue was up 6.6% on a year-over-year basis. During the same period last year, the firm posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were issued a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson's payout ratio is 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.